ArticleFrontiers in medicine2021
Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990-2019: Results From the Global Burden of Disease Study 2019.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of FAPI PET/CT in patients with lymphoma: a systematic review.Frontiers in nuclear medicine · 2025Pooled it
- Article
- Trends and projections of high body mass index-associated non-hodgkin lymphoma burden (1990-2040): A global burden of disease 2021 analysis.Annals of hematology · 2026Article
- Treatment adherence, survival outcomes and barriers to care of non-Hodgkin lymphoma in Northwest Ethiopia: a mixed-methods study.BMJ open · 2026Article
- [Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Burden of Middle-Aged and Elderly Patients With Non-Hodgkin Lymphoma From 1990 to 2021: A Systematic Analysis Based on the Global Burden of Disease 2021.Cancer medicine · 2026Article
- The global, regional, and national burden of Non-Hodgkin lymphoma in 204 countries and territories and 811 subnational locations, 1990-2021: an update from the Global Burden of Disease Study 2021.Annals of hematology · 2025Article
- The national and subnational burden of Non-Hodgkin Lymphomas (NHL) in Italy from 1990 to 2023: results from the Global Burden of Disease Study 2023.EClinicalMedicine · 2025Article
- A proof of concept study ofScientific reports · 2025Article
- Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Hematological oncology · 2025Article
- Trends of Non-Hodgkin Lymphoma Incidence Among Adults in the United States From 2000 to 2020.Cancer reports (Hoboken, N.J.) · 2025Article
- Trends and projections of Non-Hodgkin lymphoma burden (1990-2040): a global burden of disease 2021 analysis.BMC public health · 2025Article
- Lymphoma in Sub-Saharan Africa: a scoping review of the epidemiology, treatment challenges, and patient pathways.Cancer causes & control : CCC · 2025Article
- Global, regional and national temporal trends in incidence and mortality of non-Hodgkin lymphoma from 1992 to 2021: an age-period-cohort analysis.Annals of hematology · 2025Article
- Article
- A new treatment for canine B-cell lymphoma based on a recombinant single-domain antibody immunotoxin derived fromFrontiers in veterinary science · 2025Article
- Safety of Rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin's lymphoma: a retrospective study.Annals of hematology · 2024Article
- Fifteen Years of Non-Hodgkin Lymphoma in an Indonesian National Referral Hospital: Epidemiologic Trends and Diagnostic Challenges.JCO global oncology · 2024Article
- Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma.Molecular cancer therapeutics · 2024Article
- High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma.Experimental hematology & oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.